Study cases according to mutation status in pre- and post-chemotherapy samples and their clinicopathological and tumor response characteristics (n = 40 pairs).

Abbreviations: C1, + = tumor response ≥25% after cycle 1 chemotherapy, C1,— = tumour response <25% after cycle 1 chemotherapy; CR, complete response; ER, estrogen receptor status; Met, Presence of metastasis; MT, mutant; NE, non evaluable (patient had already started on another line of treatment); ORR, overall response rate; PgR, progesterone receptor; PR, partial response; SD, stable disease; T3, >50mm in greatest dimension; T4, tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules); WT, wildtype; -, negative/no; +, positive/yes a Status of respective mutation in pre-chemotherapy sample b Status of respective mutation in post-chemotherapy sample c Arm A, randomized to receive doxorubicin in first cycle; Arm B, randomized to receive docetaxel in first cycle d Age in years Study cases according to mutation status in pre- and post-chemotherapy samples and their clinicopathological and tumor response characteristics (n = 40 pairs).